MA33045B1 - PHARMACEUTICAL COMPOSITION CONTAINING LINAGLIPTIN AND OPTIONALLY SGLT-2 INHIBITOR, AND USES THEREOF - Google Patents

PHARMACEUTICAL COMPOSITION CONTAINING LINAGLIPTIN AND OPTIONALLY SGLT-2 INHIBITOR, AND USES THEREOF

Info

Publication number
MA33045B1
MA33045B1 MA34090A MA34090A MA33045B1 MA 33045 B1 MA33045 B1 MA 33045B1 MA 34090 A MA34090 A MA 34090A MA 34090 A MA34090 A MA 34090A MA 33045 B1 MA33045 B1 MA 33045B1
Authority
MA
Morocco
Prior art keywords
sglt
inhibitor
optionally
pharmaceutical composition
composition containing
Prior art date
Application number
MA34090A
Other languages
Arabic (ar)
French (fr)
Inventor
Wolfram Eisenreich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33045(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33045B1 publication Critical patent/MA33045B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق هذا الاختراع بتركيبات صيدلانية لليناغليبتين، بأشكال تقديرية صيدلانية ، بتحضيراتها، وباستخداماتها وبطرق العلاج من الاضطرابات الأيضية.This invention relates to pharmaceutical compositions of yanagliptin, in pharmaceutical discretionary forms, their preparations, their uses and methods of treatment of metabolic disorders.

MA34090A 2009-02-13 2010-02-11 PHARMACEUTICAL COMPOSITION CONTAINING LINAGLIPTIN AND OPTIONALLY SGLT-2 INHIBITOR, AND USES THEREOF MA33045B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15230609P 2009-02-13 2009-02-13
PCT/EP2010/051735 WO2010092124A1 (en) 2009-02-13 2010-02-11 Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof

Publications (1)

Publication Number Publication Date
MA33045B1 true MA33045B1 (en) 2012-02-01

Family

ID=42115453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34090A MA33045B1 (en) 2009-02-13 2010-02-11 PHARMACEUTICAL COMPOSITION CONTAINING LINAGLIPTIN AND OPTIONALLY SGLT-2 INHIBITOR, AND USES THEREOF

Country Status (31)

Country Link
US (3) US20100209506A1 (en)
EP (2) EP3144000A1 (en)
JP (1) JP5456795B2 (en)
KR (2) KR20110114658A (en)
CN (3) CN103751192A (en)
AP (1) AP2810A (en)
AR (1) AR075422A1 (en)
AU (1) AU2010212866B2 (en)
BR (1) BRPI1008556A2 (en)
CA (1) CA2752434C (en)
CL (1) CL2011001758A1 (en)
CO (1) CO6410287A2 (en)
DK (1) DK2395984T3 (en)
EA (1) EA023243B1 (en)
EC (1) ECSP11011276A (en)
ES (1) ES2606050T3 (en)
GE (1) GEP20135963B (en)
HU (1) HUE031088T2 (en)
IL (1) IL213721A0 (en)
MA (1) MA33045B1 (en)
MX (1) MX338712B (en)
MY (1) MY159630A (en)
NZ (1) NZ594022A (en)
PE (1) PE20120018A1 (en)
PL (1) PL2395984T3 (en)
SG (1) SG173036A1 (en)
TN (1) TN2011000414A1 (en)
TW (1) TWI483943B (en)
UA (1) UA103915C2 (en)
UY (1) UY32427A (en)
WO (1) WO2010092124A1 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN103467423B (en) * 2004-03-16 2016-03-16 贝林格尔.英格海姆国际有限公司 The phenyl derivatives that glucopyranosyl replaces, medicine, its purposes and manufacture method thereof containing this compound
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
UA91546C2 (en) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CA2621314A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PE20080697A1 (en) 2006-05-03 2008-08-05 Boehringer Ingelheim Int BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
US8283326B2 (en) * 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE20090938A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
CA2706018C (en) 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
CL2008003653A1 (en) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
MX2011000637A (en) 2008-07-15 2011-05-02 Theracos Inc Deuterated benzylbenzene derivatives and methods of use.
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
PE20110383A1 (en) 2008-09-08 2011-07-15 Boehringer Ingelheim Int PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A)
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (en) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 Salt forms of organic compound
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
NZ594024A (en) * 2009-02-13 2013-08-30 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
CA2752437C (en) * 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
UY32441A (en) 2009-02-13 2010-09-30 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION, TREATMENT METHODS AND ITS USES
EP2414363B1 (en) 2009-03-31 2014-01-08 Boehringer Ingelheim International GmbH 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
CA2775961C (en) 2009-09-30 2017-11-07 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
KR20210033559A (en) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
SG10201501535UA (en) * 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
CN102946875A (en) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
DK2603511T3 (en) 2010-08-12 2017-05-08 Boehringer Ingelheim Int 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2640371T (en) * 2010-11-15 2020-04-17 Boehringer Ingelheim Int Vasoprotective and cardioprotective antidiabetic therapy
AR083878A1 (en) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
AU2013214909A1 (en) 2012-02-03 2014-09-18 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy
WO2013123419A1 (en) * 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102627535A (en) * 2012-03-31 2012-08-08 天津药物研究院 Preparation method for compound containing 1,1-diphenyl cyclopropyl structure
TW201350467A (en) 2012-05-08 2013-12-16 Teva Pharma N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
JP6218811B2 (en) * 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2854812A1 (en) * 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014009970A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Linagliptin solid dispersion
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
EP3311803A1 (en) * 2012-08-13 2018-04-25 Sandoz AG Stable pharmaceutical composition containing 8-[(3r)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1h-purine-2,6-dione or a pharmaceutically acceptable salt thereof
WO2014056942A1 (en) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
JP2015535287A (en) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド Laquinimod amine salt
WO2014080384A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of linagliptin
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (en) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
DK2986304T3 (en) 2013-04-18 2022-04-04 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION, TREATMENT PROCEDURES AND USES.
TR201310724A2 (en) * 2013-09-12 2015-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical formulati̇ons of linagliptin
US9566248B2 (en) * 2013-09-13 2017-02-14 R.P. Scherer Technologies, Llc Encased-pellet tablets
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP6027710B1 (en) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 Solid preparation for diabetes treatment
CN104623684B (en) * 2015-02-11 2020-12-25 浙江华海药业股份有限公司 Preparation method of engletin mannitol composition
KR102259146B1 (en) 2015-03-05 2021-06-01 동우 화인켐 주식회사 Etchant composition for etching an indium oxide layer and method of manufacturing a display substrate using the etchant composition
EP3091076A1 (en) 2015-05-07 2016-11-09 Limagrain Europe Polynucleotide responsible of haploid induction in maize plants and related processes
WO2017060861A2 (en) * 2015-10-07 2017-04-13 Steerlife India Private Limited Rapidly disintegrating tablet compositions of dpp-iv inhibitors with low mineral content
US20180344647A1 (en) * 2015-12-04 2018-12-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN107174571B (en) * 2016-03-09 2021-01-08 四川科伦药物研究院有限公司 Pharmaceutical composition of linagliptin and salts, esters and derivatives thereof and preparation method of pharmaceutical composition
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US20180125813A1 (en) 2016-11-10 2018-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20180058510A (en) * 2016-11-24 2018-06-01 한미약품 주식회사 Pharmaceutical formulation comprising dapagliflozin l-proline
TR201720515A2 (en) * 2017-12-15 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
KR102204439B1 (en) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Pharmaceutical Composition comprising SGLT-2 inhibitor and DPP-IV inhibitor
CN111110949B (en) * 2018-11-01 2021-07-09 上海市第六人民医院 Method and device for determining insulin injection amount, computer storage medium and equipment
US11202766B1 (en) * 2019-04-23 2021-12-21 ECI Pharmaceuticals, LLC Pharmaceutical compositions including hydrocodone bitartrate and guaifenesin

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969349B1 (en) 1997-09-17 2005-11-29 Origin Medsystem, Inc. Device to permit offpump beating heart coronary bypass surgery
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
PL216134B1 (en) * 2002-08-21 2014-03-31 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
US7674486B2 (en) * 2003-05-14 2010-03-09 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
SI1715893T1 (en) 2004-01-20 2009-12-31 Novartis Pharma Ag Direct compression formulation and process
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN103467423B (en) * 2004-03-16 2016-03-16 贝林格尔.英格海姆国际有限公司 The phenyl derivatives that glucopyranosyl replaces, medicine, its purposes and manufacture method thereof containing this compound
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
TW200635599A (en) 2004-12-16 2006-10-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
GT200600008A (en) * 2005-01-18 2006-08-09 FORMULATION OF DIRECT COMPRESSION AND PROCESS
CN101106977A (en) * 2005-01-18 2008-01-16 诺瓦提斯公司 Direct compression formulation and process
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
UA91546C2 (en) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
GT200600218A (en) * 2005-06-10 2007-03-28 FORMULATION AND PROCESS OF DIRECT COMPRESSION
JP5175191B2 (en) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glycopyranosyl-substituted benzylbenzene derivative, pharmaceutical containing the compound, and use and production method thereof
CA2621314A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(.beta.-d-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (en) 2005-09-15 2007-09-26 Boehringer Ingelheim Int PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
WO2007039417A1 (en) * 2005-09-30 2007-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing meloxicam
JP2009531291A (en) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing these compounds, their use and methods of manufacture
PE20080697A1 (en) 2006-05-03 2008-08-05 Boehringer Ingelheim Int BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
PE20110235A1 (en) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7879806B2 (en) 2006-11-06 2011-02-01 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
UA100008C2 (en) * 2006-11-09 2012-11-12 Бьорінгер Інгельхайм Інтернаціональ Гмбх Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
PE20090938A1 (en) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
CL2008002425A1 (en) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising an inhibitor of sglt2 and 1- (4-methyl-quinazolin-2-yl) methyl-3-methyl-7 - (- 2-butin-1-yl) -8- (3- (r) -amino- Piperidin-1yl) -xanthine, an iv dpp inhibitor and its use for the treatment of obesity and type 1 and 2 diabetes and complications thereof.
CL2008003653A1 (en) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
AR071175A1 (en) * 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
US20090279199A1 (en) 2008-05-12 2009-11-12 Samsung Electronics Co., Ltd. Method and apparatus for reducing slider contact probability in a load-unload (LUL) hard disk drive
UY32427A (en) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME

Also Published As

Publication number Publication date
EP2395984A1 (en) 2011-12-21
WO2010092124A1 (en) 2010-08-19
TW201040185A (en) 2010-11-16
IL213721A0 (en) 2011-07-31
CN103751192A (en) 2014-04-30
KR101894228B1 (en) 2018-09-04
CL2011001758A1 (en) 2011-10-28
UA103915C2 (en) 2013-12-10
HUE031088T2 (en) 2017-06-28
CA2752434A1 (en) 2010-08-19
AU2010212866A1 (en) 2011-07-21
SG173036A1 (en) 2011-08-29
US20180104249A1 (en) 2018-04-19
KR20110114658A (en) 2011-10-19
GEP20135963B (en) 2013-11-11
EA201101190A1 (en) 2012-05-30
US20220331326A1 (en) 2022-10-20
ECSP11011276A (en) 2011-09-30
ES2606050T3 (en) 2017-03-17
AU2010212866B2 (en) 2013-06-06
CA2752434C (en) 2017-07-11
NZ594022A (en) 2013-07-26
PE20120018A1 (en) 2012-02-12
AP2011005776A0 (en) 2011-06-30
US20100209506A1 (en) 2010-08-19
MY159630A (en) 2017-01-13
BRPI1008556A2 (en) 2020-07-14
CO6410287A2 (en) 2012-03-30
JP5456795B2 (en) 2014-04-02
AP2810A (en) 2013-12-31
CN103751193B (en) 2018-09-21
TWI483943B (en) 2015-05-11
DK2395984T3 (en) 2016-12-19
EP3144000A1 (en) 2017-03-22
KR20170039771A (en) 2017-04-11
EA023243B1 (en) 2016-05-31
CN102316861A (en) 2012-01-11
AR075422A1 (en) 2011-03-30
JP2012517458A (en) 2012-08-02
CN103751193A (en) 2014-04-30
EP2395984B1 (en) 2016-10-19
UY32427A (en) 2010-09-30
MX2011008171A (en) 2011-08-17
MX338712B (en) 2016-04-28
PL2395984T3 (en) 2017-04-28
TN2011000414A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
MA33045B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LINAGLIPTIN AND OPTIONALLY SGLT-2 INHIBITOR, AND USES THEREOF
MA33044B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, ITS GALENIC DOSAGE FORM, PREPARATION METHOD AND USES FOR ENHANCED GLYCEMIC REGULATION IN PATIENT
MA32393B1 (en) Compounds and compounds that act as kinase inhibitors
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
EA028156B9 (en) Fused heterocyclic compounds as ion channel modulators
EA200870216A1 (en) AMIDO COMPOUNDS AND THEIR APPLICATION AS MEDICINES
PH12014500053A1 (en) Proteasome inhibitors
EA201170508A1 (en) DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBURONIC ACID
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
UA107783C2 (en) Isoindoline compounds for use in treating cancer
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EA201170349A1 (en) MIF MODULATORS
MX2018009945A (en) Novel compositions and methods for the treatment of immune related diseases.
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA201291336A1 (en) SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINE AND THEIR APPLICATION
IN2012DN00971A (en)
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
EA201171435A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR PRODUCTION
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
NO20062739L (en) Controlled release of topirimate in liquid dosage form
EA201200570A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
ATE555116T1 (en) AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
UA107204C2 (en) ANTI-FUNCTIONAL COMPOSITION CONTAINING THE PYTHIUM OLIGANDRUM Fungal Organism